Description:

Size: 100ul

Catalog no.: bs-0338R-A594

Price: 380 EUR

Product details

Modification Site

None

Crossreactivity

Virus

Swiss Prot

Q9DXH4

Tested applications

IF(IHC-P)

French translation

anticorps

Modification

Unmodified

Clonality

Polyclonal

Excitation emission

590nm/617nm

Concentration

1ug per 1ul

Immunogen range

2420-2439/2842

Target Antigen

HGV Polyprotein

Cross-reactive species details

Hepatitis G Virus

Conjugated with

ALEXA FLUOR® 594

Conjugated

Alexa conjugate 1

Recommended dilutions

IF(IHC-P)(1:50-200)

Clone

Polyclonal antibody

Purification

Purified by Protein A.

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Category

Conjugated Primary Antibodies

Host Organism

Rabbit (Oryctolagus cuniculus)

Also known as

Anti-HGV Polyprotein PAb ALEXA FLUOR 594

Specificity

This is a highly specific antibody against HGV Polyprotein.

Long name

HGV Polyprotein Polyclonal Antibody, ALEXA FLUOR 594 Conjugated

Source

KLH conjugated synthetic peptide derived from Hepatitis G Virus Polyprotein

Synonyms

Polyprotein [Hepatitis G virus isolate PE]; Hepatitis G Virus; Hepatitis GB virus C; HGV.

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Properties

For facs or microscopy Alexa 1 conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the antigen

Hepatitis G virus is from a group of viruses called GB viruses (GB virus A, GB virus B and GB virus C) and is also designated as GB virus C (GBV C). HGV is a positive stranded RNA virus, with a genome of 10 KB and appears, on the basis of genome length and organisation, to be a member of the Flaviviridae and distinct from the hepatitis C virus (HCV). HGV infection appears to be transmitted following receipt of blood from HGV RNA positive donors, however, these patients have only moderate liver enzyme elevations and do not develop chronic liver disease.